Adrien D. V.
- Country
- Belgium
- Department
- Hematology
Research Overview
- Efficacy of Ziftomenib Combined with Standard of Care Therapy in Patients with Untreated NPM1-Mutated or KMT2A-Rearranged Acute Myeloid Leukemia
- Phase 2 Randomized Study of EL219 Versus Liposomal Amphotericin B and Voriconazole for Early Antifungal Therapy of Suspected Invasive Mould Infections
- Phase II Multicenter Randomized Trial of WT1 mRNA-Electroporated Dendritic Cell Vaccination for Relapse Prevention in Adult Acute Myeloid Leukemia
Data & Insights
Has run more than one trial at 177 of 298 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in the treatment of acute myeloid leukemia (AML), with particular emphasis on novel therapeutic approaches for different genetic subtypes including IDH1-mutated and FLT3-ITD negative AML.
- Targeted Therapy Development
- Combination Treatment Strategies
- Genetic Mutation Analysis
Research activities focus on developing personalized treatment approaches for patients ineligible for intensive chemotherapy.
Immunotherapy Research
Advancing innovative immunotherapeutic approaches through dendritic cell vaccination strategies, particularly focusing on WT1 antigen-targeted therapy for leukemia patients in remission.
- Cancer Vaccines
- Post-remission Strategies
- Relapse Prevention
The research explores novel immunological interventions to improve long-term survival outcomes.
Supportive Care Medicine
Expertise in managing febrile neutropenia in hematology patients, with focus on optimizing antibiotic treatment protocols and developing evidence-based approaches to infection management.
- Antibiotic Strategy Optimization
- Infection Management
- Treatment Duration Assessment
Investigation of shorter duration therapeutic approaches for neutropenic complications.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.